FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis

Synopsis

FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis The FDA granted accelerated approval of Voceryq to Inovio Pharmaceuticals, Inc.

Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.